A5068927620- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CNS Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Immune Cell Function and Interaction
- Glycosylation and Glycoproteins Research
- Medical Imaging Techniques and Applications
- Bone health and treatments
- Eosinophilic Disorders and Syndromes
- Hematopoietic Stem Cell Transplantation
- Cancer Immunotherapy and Biomarkers
- Blood groups and transfusion
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Gastrointestinal Tumor Research and Treatment
National and Kapodistrian University of Athens
2016-2025
Laiko General Hospital of Athens
2016-2025
Centre Antoine Lacassagne
2024
Martin Luther University Halle-Wittenberg
2023
General Hospital of Attica
2018-2019
City Of Hope National Medical Center
2017
Dana-Farber Cancer Institute
2017
Jewish General Hospital
2017
Institut Gustave Roussy
2017
The University of Texas MD Anderson Cancer Center
2002-2017
Purpose Hodgkin Reed-Sternberg cells harbor alterations in chromosome 9p24.1, leading to overexpression of programmed death-ligand 1 (PD-L1) and PD-L2. Pembrolizumab, a death 1-blocking antibody, demonstrated high overall response rate (ORR) patients with relapsed or refractory classic lymphoma (rrHL) phase I testing. Methods KEYNOTE-087 ( ClinicalTrials.gov identifier, NCT02453594) was single-arm II study pembrolizumab three cohorts rrHL, defined on the basis progression after (1)...
Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome who receive a second course after treatment discontinuation complete (CR) remain clinical interest. We present data >5 years median follow-up. Patients R/R cHL progressive disease (PD) autologous stem cell...
More aggressive treatment approaches (methotrexate, cytarabine, cyclophosphamide, vincristine, prednisone, and bleomycin [the MACOP-B regimen] or consolidation with high-dose therapy autologous stem cell transplantation) have been considered to be superior doxorubicin, prednisone (CHOP) in patients primary mediastinal large B-cell lymphoma (PMLBCL). Rituximab-CHOP (R-CHOP) is the standard of care for diffuse lymphoma, whereas efficacy PMLBCL has not adequately confirmed.Seventy-six...
Summary The prognostic value of baseline serum free light chain ratio (sFLCR) was investigated in 94 multiple myeloma (MM) patients. sFLCR calculated as κ / λ or , depending on the patients’ dominating monoclonal chain. Median 3·57 ‐MM patients, 45·09 ‐MM. ‘High’ (≥ observed median for ‐ and respectively) correlated with elevated creatinine lactate dehydrogenase, extensive marrow infiltration type MM. 5‐year disease‐specific survival 82% 30% patients lower than equal greater median,...
Abstract Background. Treatment of splenic marginal zone lymphoma (SMZL) patients is not standardized. Recent data suggest that rituximab highly effective and could be considered as initial therapy. Aim. To assess the efficacy monotherapy in a large series with SMZL compare these results splenectomy results. Methods. The studied population included 85 patients. Fifty-eight received at dose 375 mg/m2 per week for 6 weeks induction followed by maintenance same every 2 months 1–2 years, whereas...
Emerging data suggest suboptimal antibody responses to COVID-19 vaccination in patients with hematological malignancies. We evaluated the humoral response following BNT162b2 vaccine chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and Hodgkin's (HL). An FDA-approved, ELISA-based methodology was implemented evaluate titers of neutralizing antibodies (NAbs) against SARS-CoV-2 on day 1 first vaccine, afterwards 22 50. One hundred thirty-two CLL/lymphomas 214 healthy matched...
Hepcidin is a 25-aminoacid cysteine-rich iron regulating peptide. Increased hepcidin concentrations lead to sequestration in macrophages, contributing the pathogenesis of anaemia chronic disease whereas decreased observed deficiency and primary overload diseases such as hereditary hemochromatosis. quantification human blood or urine may provide further insights for disorders homeostasis might prove valuable tool clinicians differential diagnosis anaemia. This study describes specific...
Abstract International Staging System (ISS), serum free light chain ratio (sFLCR) and lactate dehydrogenase (LDH) are well known, easily assessed independent prognostic indicators of outcome in multiple myeloma (MM). The purpose the study was to re‐examine contribution these variables a multicenter setting with special attention MM patients treated autologous stem cell transplantation (ASCT) or novel agents (NA). Three hundred five symptomatic newly diagnosed were retrospectively studied....
Abstract Transplant‐ineligible relapsed/refractory (rr) diffuse large B‐cell lymphoma (DLBCL) patients represent an unmet medical need. Polatuzumab vedotin (Pola), anti‐CD79b antibody‐drug‐conjugate (ADG), with bendamustine‐ rituximab(BR) has recently gained approval for these patients, both in the USA and Europe, based on GO29365 phase IIb trial. Real‐life data Pola are extremely limited. We report outcomes of 61 Greek who received Pola‐(B)R mainly within a compassionate use program....
PURPOSE: CD20 can be expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin’s disease (HD), but its clinical significance remains controversial. Therefore, we correlated expression with presenting features outcome untreated patients HD. PATIENTS AND METHODS: Patients were eligible if they previously human immunodeficiency virus-1 negative, had biopsy-proven HD, pretreatment paraffin-embedded tumor tissue was available. determined by immunohistochemistry without knowledge...
Abstract Objectives To evaluate the prognostic impact of hypercalcemia in newly diagnosed patients with symptomatic multiple myeloma ( MM ), especially after incorporation new agents. Methods we analyzed outcomes included database Greek Myeloma Study Group for effect presence (defined as corrected serum calcium ≥11 mg/ dL ) at diagnosis. Results Among 2129 consecutive , 19.5% presented time The was associated anemia, thrombocytopenia, lower estimated glomerular filtration rate eGFR advanced...
Primary mediastinal large B-cell lymphoma (PMBCL) is a rare aggressive predominantly affecting young female patients. Large-scale genomic investigations and genetic markers for risk stratification are lacking.